Virax Biolabs Group Limited (VRAX) Stock Competitors & Peer Comparison
See (VRAX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VRAX | $6.36 | +100.00% | 1.2M | -0.10 | -$61.75 | N/A |
| VRTX | $496.50 | -0.39% | 126B | 26.38 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $668.13 | +0.79% | 68.8B | 14.64 | $45.63 | +0.55% |
| ARGX | $909.64 | -0.62% | 56.6B | 82.08 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $314.70 | -2.72% | 41.8B | 56.36 | $5.55 | N/A |
| RVMDW | $9.86 | +2.02% | 41.2B | -2.38 | -$4.15 | N/A |
| RVMD | $191.13 | +0.72% | 40.6B | -27.03 | -$7.07 | N/A |
| ONC | $303.92 | +0.68% | 32.4B | 67.75 | $4.47 | N/A |
Stock Comparison
VRAX vs VRTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, VRTX has a market cap of 126B. Regarding current trading prices, VRAX is priced at $6.36, while VRTX trades at $496.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas VRTX's P/E ratio is 26.38. In terms of profitability, VRAX's ROE is -1.03%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, VRAX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check VRTX's competition here
VRAX vs VRNA Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VRAX is priced at $6.36, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VRAX's ROE is -1.03%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, VRAX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check VRNA's competition here
VRAX vs REGN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, REGN has a market cap of 68.8B. Regarding current trading prices, VRAX is priced at $6.36, while REGN trades at $668.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas REGN's P/E ratio is 14.64. In terms of profitability, VRAX's ROE is -1.03%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VRAX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check REGN's competition here
VRAX vs ARGX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ARGX has a market cap of 56.6B. Regarding current trading prices, VRAX is priced at $6.36, while ARGX trades at $909.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ARGX's P/E ratio is 82.08. In terms of profitability, VRAX's ROE is -1.03%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, VRAX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ARGX's competition here
VRAX vs SGEN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRAX is priced at $6.36, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRAX's ROE is -1.03%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRAX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SGEN's competition here
VRAX vs ALNY Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ALNY has a market cap of 41.8B. Regarding current trading prices, VRAX is priced at $6.36, while ALNY trades at $314.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ALNY's P/E ratio is 56.36. In terms of profitability, VRAX's ROE is -1.03%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, VRAX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ALNY's competition here
VRAX vs RVMDW Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, RVMDW has a market cap of 41.2B. Regarding current trading prices, VRAX is priced at $6.36, while RVMDW trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas RVMDW's P/E ratio is -2.38. In terms of profitability, VRAX's ROE is -1.03%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, VRAX is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for VRAX.Check RVMDW's competition here
VRAX vs RVMD Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, VRAX is priced at $6.36, while RVMD trades at $191.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas RVMD's P/E ratio is -27.03. In terms of profitability, VRAX's ROE is -1.03%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, VRAX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RVMD's competition here
VRAX vs ONC Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ONC has a market cap of 32.4B. Regarding current trading prices, VRAX is priced at $6.36, while ONC trades at $303.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ONC's P/E ratio is 67.75. In terms of profitability, VRAX's ROE is -1.03%, compared to ONC's ROE of +0.12%. Regarding short-term risk, VRAX is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ONC's competition here
VRAX vs MRNA Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, MRNA has a market cap of 30.4B. Regarding current trading prices, VRAX is priced at $6.36, while MRNA trades at $76.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas MRNA's P/E ratio is -9.39. In terms of profitability, VRAX's ROE is -1.03%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, VRAX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MRNA's competition here
VRAX vs ROIV Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ROIV has a market cap of 26.5B. Regarding current trading prices, VRAX is priced at $6.36, while ROIV trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ROIV's P/E ratio is -37.84. In terms of profitability, VRAX's ROE is -1.03%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, VRAX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ROIV's competition here
VRAX vs INSM Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, INSM has a market cap of 25.6B. Regarding current trading prices, VRAX is priced at $6.36, while INSM trades at $118.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas INSM's P/E ratio is -20.57. In terms of profitability, VRAX's ROE is -1.03%, compared to INSM's ROE of -1.30%. Regarding short-term risk, VRAX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check INSM's competition here
VRAX vs INCY Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, VRAX is priced at $6.36, while INCY trades at $118.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas INCY's P/E ratio is 15.93. In terms of profitability, VRAX's ROE is -1.03%, compared to INCY's ROE of +0.29%. Regarding short-term risk, VRAX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check INCY's competition here
VRAX vs BNTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, BNTX has a market cap of 23.5B. Regarding current trading prices, VRAX is priced at $6.36, while BNTX trades at $92.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas BNTX's P/E ratio is -20.13. In terms of profitability, VRAX's ROE is -1.03%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, VRAX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BNTX's competition here
VRAX vs UTHR Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, UTHR has a market cap of 23.5B. Regarding current trading prices, VRAX is priced at $6.36, while UTHR trades at $552.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas UTHR's P/E ratio is 20.39. In terms of profitability, VRAX's ROE is -1.03%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VRAX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check UTHR's competition here
VRAX vs BGNE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRAX is priced at $6.36, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRAX's ROE is -1.03%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, VRAX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BGNE's competition here
VRAX vs DNA-WT Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRAX is priced at $6.36, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRAX's ROE is -1.03%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, VRAX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DNA-WT's competition here
VRAX vs GMAB Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, GMAB has a market cap of 18.3B. Regarding current trading prices, VRAX is priced at $6.36, while GMAB trades at $29.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas GMAB's P/E ratio is 21.42. In terms of profitability, VRAX's ROE is -1.03%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, VRAX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check GMAB's competition here
VRAX vs NBIX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, NBIX has a market cap of 18.2B. Regarding current trading prices, VRAX is priced at $6.36, while NBIX trades at $180.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas NBIX's P/E ratio is 26.09. In terms of profitability, VRAX's ROE is -1.03%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, VRAX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check NBIX's competition here
VRAX vs BBIO Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, BBIO has a market cap of 17.7B. Regarding current trading prices, VRAX is priced at $6.36, while BBIO trades at $90.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas BBIO's P/E ratio is -24.11. In terms of profitability, VRAX's ROE is -1.03%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, VRAX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BBIO's competition here
VRAX vs ASND Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ASND has a market cap of 17.1B. Regarding current trading prices, VRAX is priced at $6.36, while ASND trades at $275.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ASND's P/E ratio is -113.81. In terms of profitability, VRAX's ROE is -1.03%, compared to ASND's ROE of -56.42%. Regarding short-term risk, VRAX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ASND's competition here
VRAX vs JAZZ Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, VRAX is priced at $6.36, while JAZZ trades at $247.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas JAZZ's P/E ratio is 19.20. In terms of profitability, VRAX's ROE is -1.03%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, VRAX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check JAZZ's competition here
VRAX vs EXEL Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, EXEL has a market cap of 14.4B. Regarding current trading prices, VRAX is priced at $6.36, while EXEL trades at $56.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas EXEL's P/E ratio is 17.10. In terms of profitability, VRAX's ROE is -1.03%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, VRAX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check EXEL's competition here
VRAX vs MDGL Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, MDGL has a market cap of 12.9B. Regarding current trading prices, VRAX is priced at $6.36, while MDGL trades at $557.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas MDGL's P/E ratio is -43.75. In terms of profitability, VRAX's ROE is -1.03%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, VRAX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MDGL's competition here
VRAX vs AXSM Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, AXSM has a market cap of 12.8B. Regarding current trading prices, VRAX is priced at $6.36, while AXSM trades at $247.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas AXSM's P/E ratio is -64.99. In terms of profitability, VRAX's ROE is -1.03%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, VRAX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check AXSM's competition here
VRAX vs KRTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRAX is priced at $6.36, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRAX's ROE is -1.03%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRAX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check KRTX's competition here
VRAX vs SMMT Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, VRAX is priced at $6.36, while SMMT trades at $15.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas SMMT's P/E ratio is -9.67. In terms of profitability, VRAX's ROE is -1.03%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, VRAX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SMMT's competition here
VRAX vs ARWR Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ARWR has a market cap of 11.8B. Regarding current trading prices, VRAX is priced at $6.36, while ARWR trades at $83.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ARWR's P/E ratio is -39.07. In terms of profitability, VRAX's ROE is -1.03%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, VRAX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ARWR's competition here
VRAX vs BMRN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, VRAX is priced at $6.36, while BMRN trades at $59.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas BMRN's P/E ratio is 28.83. In terms of profitability, VRAX's ROE is -1.03%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, VRAX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BMRN's competition here
VRAX vs RNAM Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VRAX is priced at $6.36, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VRAX's ROE is -1.03%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VRAX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RNAM's competition here
VRAX vs TECH Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, VRAX is priced at $6.36, while TECH trades at $71.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas TECH's P/E ratio is 36.68. In terms of profitability, VRAX's ROE is -1.03%, compared to TECH's ROE of +0.05%. Regarding short-term risk, VRAX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TECH's competition here
VRAX vs KRYS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, KRYS has a market cap of 10.9B. Regarding current trading prices, VRAX is priced at $6.36, while KRYS trades at $370.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas KRYS's P/E ratio is 49.63. In terms of profitability, VRAX's ROE is -1.03%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VRAX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check KRYS's competition here
VRAX vs CYTK Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CYTK has a market cap of 10.7B. Regarding current trading prices, VRAX is priced at $6.36, while CYTK trades at $85.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CYTK's P/E ratio is -14.76. In terms of profitability, VRAX's ROE is -1.03%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, VRAX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CYTK's competition here
VRAX vs IONS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, IONS has a market cap of 10.6B. Regarding current trading prices, VRAX is priced at $6.36, while IONS trades at $64.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas IONS's P/E ratio is -37.37. In terms of profitability, VRAX's ROE is -1.03%, compared to IONS's ROE of -0.59%. Regarding short-term risk, VRAX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IONS's competition here
VRAX vs CORT Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CORT has a market cap of 10B. Regarding current trading prices, VRAX is priced at $6.36, while CORT trades at $92.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CORT's P/E ratio is 266.43. In terms of profitability, VRAX's ROE is -1.03%, compared to CORT's ROE of +0.08%. Regarding short-term risk, VRAX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CORT's competition here
VRAX vs KYMR Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, KYMR has a market cap of 9.8B. Regarding current trading prices, VRAX is priced at $6.36, while KYMR trades at $118.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas KYMR's P/E ratio is -33.71. In terms of profitability, VRAX's ROE is -1.03%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, VRAX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check KYMR's competition here
VRAX vs RXDX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRAX is priced at $6.36, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRAX's ROE is -1.03%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRAX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RXDX's competition here
VRAX vs HALO Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, HALO has a market cap of 9.3B. Regarding current trading prices, VRAX is priced at $6.36, while HALO trades at $78.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas HALO's P/E ratio is 17.02. In terms of profitability, VRAX's ROE is -1.03%, compared to HALO's ROE of +1.26%. Regarding short-term risk, VRAX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check HALO's competition here
VRAX vs IBRX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, IBRX has a market cap of 9.3B. Regarding current trading prices, VRAX is priced at $6.36, while IBRX trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas IBRX's P/E ratio is -27.72. In terms of profitability, VRAX's ROE is -1.03%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, VRAX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IBRX's competition here
VRAX vs ABVX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, VRAX is priced at $6.36, while ABVX trades at $140.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ABVX's P/E ratio is -73.61. In terms of profitability, VRAX's ROE is -1.03%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VRAX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ABVX's competition here
VRAX vs NUVL Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VRAX is priced at $6.36, while NUVL trades at $123.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas NUVL's P/E ratio is -21.76. In terms of profitability, VRAX's ROE is -1.03%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VRAX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check NUVL's competition here
VRAX vs TGTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, TGTX has a market cap of 9B. Regarding current trading prices, VRAX is priced at $6.36, while TGTX trades at $59.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas TGTX's P/E ratio is 20.30. In terms of profitability, VRAX's ROE is -1.03%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, VRAX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TGTX's competition here
VRAX vs PTGX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, VRAX is priced at $6.36, while PTGX trades at $137.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas PTGX's P/E ratio is -77.39. In terms of profitability, VRAX's ROE is -1.03%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, VRAX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PTGX's competition here
VRAX vs ALKS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ALKS has a market cap of 9B. Regarding current trading prices, VRAX is priced at $6.36, while ALKS trades at $53.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ALKS's P/E ratio is 56.61. In terms of profitability, VRAX's ROE is -1.03%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, VRAX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ALKS's competition here
VRAX vs CRNX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, VRAX is priced at $6.36, while CRNX trades at $83.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CRNX's P/E ratio is -16.30. In terms of profitability, VRAX's ROE is -1.03%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VRAX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CRNX's competition here
VRAX vs IMGN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRAX is priced at $6.36, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRAX's ROE is -1.03%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VRAX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IMGN's competition here
VRAX vs PCVX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, VRAX is priced at $6.36, while PCVX trades at $60.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas PCVX's P/E ratio is -8.70. In terms of profitability, VRAX's ROE is -1.03%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, VRAX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PCVX's competition here
VRAX vs IMVT Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, IMVT has a market cap of 8.4B. Regarding current trading prices, VRAX is priced at $6.36, while IMVT trades at $41.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas IMVT's P/E ratio is -15.39. In terms of profitability, VRAX's ROE is -1.03%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, VRAX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check IMVT's competition here
VRAX vs BPMC Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRAX is priced at $6.36, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRAX's ROE is -1.03%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VRAX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BPMC's competition here
VRAX vs APGE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, VRAX is priced at $6.36, while APGE trades at $133.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas APGE's P/E ratio is -30.85. In terms of profitability, VRAX's ROE is -1.03%, compared to APGE's ROE of -0.33%. Regarding short-term risk, VRAX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check APGE's competition here
VRAX vs CERE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRAX is priced at $6.36, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRAX's ROE is -1.03%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VRAX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CERE's competition here
VRAX vs RYTM Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, VRAX is priced at $6.36, while RYTM trades at $115.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas RYTM's P/E ratio is -36.89. In terms of profitability, VRAX's ROE is -1.03%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, VRAX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RYTM's competition here
VRAX vs MTSR Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VRAX is priced at $6.36, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VRAX's ROE is -1.03%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, VRAX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MTSR's competition here
VRAX vs PTCT Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, PTCT has a market cap of 7.3B. Regarding current trading prices, VRAX is priced at $6.36, while PTCT trades at $89.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas PTCT's P/E ratio is -38.01. In terms of profitability, VRAX's ROE is -1.03%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, VRAX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PTCT's competition here
VRAX vs LQDA Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, LQDA has a market cap of 7.2B. Regarding current trading prices, VRAX is priced at $6.36, while LQDA trades at $81.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas LQDA's P/E ratio is 581.79. In terms of profitability, VRAX's ROE is -1.03%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, VRAX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check LQDA's competition here
VRAX vs PRAX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, VRAX is priced at $6.36, while PRAX trades at $336.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas PRAX's P/E ratio is -24.91. In terms of profitability, VRAX's ROE is -1.03%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, VRAX is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check PRAX's competition here
VRAX vs SRRK Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, SRRK has a market cap of 6.9B. Regarding current trading prices, VRAX is priced at $6.36, while SRRK trades at $57.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas SRRK's P/E ratio is -16.14. In terms of profitability, VRAX's ROE is -1.03%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, VRAX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SRRK's competition here
VRAX vs COGT Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, VRAX is priced at $6.36, while COGT trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas COGT's P/E ratio is -19.20. In terms of profitability, VRAX's ROE is -1.03%, compared to COGT's ROE of -0.83%. Regarding short-term risk, VRAX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check COGT's competition here
VRAX vs MRUS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VRAX is priced at $6.36, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VRAX's ROE is -1.03%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, VRAX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MRUS's competition here
VRAX vs ACLX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VRAX is priced at $6.36, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VRAX's ROE is -1.03%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VRAX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ACLX's competition here
VRAX vs RETA Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRAX is priced at $6.36, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRAX's ROE is -1.03%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRAX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RETA's competition here
VRAX vs CGON Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, VRAX is priced at $6.36, while CGON trades at $73.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CGON's P/E ratio is -31.47. In terms of profitability, VRAX's ROE is -1.03%, compared to CGON's ROE of -0.23%. Regarding short-term risk, VRAX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CGON's competition here
VRAX vs LGND Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, LGND has a market cap of 6.5B. Regarding current trading prices, VRAX is priced at $6.36, while LGND trades at $321.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas LGND's P/E ratio is 38.68. In terms of profitability, VRAX's ROE is -1.03%, compared to LGND's ROE of +0.16%. Regarding short-term risk, VRAX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check LGND's competition here
VRAX vs MIRM Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, MIRM has a market cap of 6.4B. Regarding current trading prices, VRAX is priced at $6.36, while MIRM trades at $127.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas MIRM's P/E ratio is -9.38. In terms of profitability, VRAX's ROE is -1.03%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, VRAX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MIRM's competition here
VRAX vs CNTA Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VRAX is priced at $6.36, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VRAX's ROE is -1.03%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VRAX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CNTA's competition here
VRAX vs BLTE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, VRAX is priced at $6.36, while BLTE trades at $153.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas BLTE's P/E ratio is -81.95. In terms of profitability, VRAX's ROE is -1.03%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, VRAX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check BLTE's competition here
VRAX vs ERAS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ERAS has a market cap of 6B. Regarding current trading prices, VRAX is priced at $6.36, while ERAS trades at $19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ERAS's P/E ratio is -43.59. In terms of profitability, VRAX's ROE is -1.03%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, VRAX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ERAS's competition here
VRAX vs SYRE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, SYRE has a market cap of 6B. Regarding current trading prices, VRAX is priced at $6.36, while SYRE trades at $98.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas SYRE's P/E ratio is -47.48. In terms of profitability, VRAX's ROE is -1.03%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, VRAX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check SYRE's competition here
VRAX vs CDTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VRAX is priced at $6.36, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VRAX's ROE is -1.03%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, VRAX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CDTX's competition here
VRAX vs XENE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, XENE has a market cap of 5.6B. Regarding current trading prices, VRAX is priced at $6.36, while XENE trades at $70.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas XENE's P/E ratio is -15.10. In terms of profitability, VRAX's ROE is -1.03%, compared to XENE's ROE of -0.49%. Regarding short-term risk, VRAX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check XENE's competition here
VRAX vs CELC Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CELC has a market cap of 5.5B. Regarding current trading prices, VRAX is priced at $6.36, while CELC trades at $113.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CELC's P/E ratio is -29.11. In terms of profitability, VRAX's ROE is -1.03%, compared to CELC's ROE of -2.45%. Regarding short-term risk, VRAX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CELC's competition here
VRAX vs ABCM Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRAX is priced at $6.36, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRAX's ROE is -1.03%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRAX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ABCM's competition here
VRAX vs ISEE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRAX is priced at $6.36, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRAX's ROE is -1.03%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRAX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ISEE's competition here
VRAX vs TVTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, TVTX has a market cap of 5.4B. Regarding current trading prices, VRAX is priced at $6.36, while TVTX trades at $58.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas TVTX's P/E ratio is -265.77. In terms of profitability, VRAX's ROE is -1.03%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, VRAX is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TVTX's competition here
VRAX vs CRSP Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, VRAX is priced at $6.36, while CRSP trades at $56.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CRSP's P/E ratio is -11.03. In terms of profitability, VRAX's ROE is -1.03%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, VRAX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CRSP's competition here
VRAX vs DFTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, DFTX has a market cap of 5.3B. Regarding current trading prices, VRAX is priced at $6.36, while DFTX trades at $48.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas DFTX's P/E ratio is N/A. In terms of profitability, VRAX's ROE is -1.03%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, VRAX is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DFTX's competition here
VRAX vs APLS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VRAX is priced at $6.36, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas APLS's P/E ratio is 38.35. In terms of profitability, VRAX's ROE is -1.03%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VRAX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check APLS's competition here
VRAX vs MANE Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, MANE has a market cap of 5.2B. Regarding current trading prices, VRAX is priced at $6.36, while MANE trades at $124.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas MANE's P/E ratio is -39.80. In terms of profitability, VRAX's ROE is -1.03%, compared to MANE's ROE of -0.84%. Regarding short-term risk, VRAX is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MANE's competition here
VRAX vs EWTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, EWTX has a market cap of 5.2B. Regarding current trading prices, VRAX is priced at $6.36, while EWTX trades at $48.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas EWTX's P/E ratio is -29.13. In terms of profitability, VRAX's ROE is -1.03%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, VRAX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check EWTX's competition here
VRAX vs LEGN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, LEGN has a market cap of 5.1B. Regarding current trading prices, VRAX is priced at $6.36, while LEGN trades at $27.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas LEGN's P/E ratio is -40.26. In terms of profitability, VRAX's ROE is -1.03%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, VRAX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check LEGN's competition here
VRAX vs CAI Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, VRAX is priced at $6.36, while CAI trades at $17.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CAI's P/E ratio is -98.29. In terms of profitability, VRAX's ROE is -1.03%, compared to CAI's ROE of +0.06%. Regarding short-term risk, VRAX is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CAI's competition here
VRAX vs VKTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, VKTX has a market cap of 4.8B. Regarding current trading prices, VRAX is priced at $6.36, while VKTX trades at $41.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas VKTX's P/E ratio is -9.94. In terms of profitability, VRAX's ROE is -1.03%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, VRAX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check VKTX's competition here
VRAX vs TERN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VRAX is priced at $6.36, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas TERN's P/E ratio is -51.41. In terms of profitability, VRAX's ROE is -1.03%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VRAX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TERN's competition here
VRAX vs FOLD Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VRAX is priced at $6.36, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VRAX's ROE is -1.03%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VRAX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check FOLD's competition here
VRAX vs ACAD Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, VRAX is priced at $6.36, while ACAD trades at $26.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ACAD's P/E ratio is 12.95. In terms of profitability, VRAX's ROE is -1.03%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, VRAX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ACAD's competition here
VRAX vs AKRO Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VRAX is priced at $6.36, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VRAX's ROE is -1.03%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, VRAX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check AKRO's competition here
VRAX vs ALPN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRAX is priced at $6.36, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRAX's ROE is -1.03%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VRAX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ALPN's competition here
VRAX vs NAMSW Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, NAMSW has a market cap of 4.3B. Regarding current trading prices, VRAX is priced at $6.36, while NAMSW trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, VRAX's ROE is -1.03%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, VRAX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check NAMSW's competition here
VRAX vs DNLI Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, DNLI has a market cap of 4.3B. Regarding current trading prices, VRAX is priced at $6.36, while DNLI trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas DNLI's P/E ratio is -9.45. In terms of profitability, VRAX's ROE is -1.03%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, VRAX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DNLI's competition here
VRAX vs OPT Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRAX is priced at $6.36, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRAX's ROE is -1.03%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VRAX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check OPT's competition here
VRAX vs NAMS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, NAMS has a market cap of 4.2B. Regarding current trading prices, VRAX is priced at $6.36, while NAMS trades at $36.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas NAMS's P/E ratio is -22.59. In terms of profitability, VRAX's ROE is -1.03%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, VRAX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check NAMS's competition here
VRAX vs DNTH Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, DNTH has a market cap of 4.2B. Regarding current trading prices, VRAX is priced at $6.36, while DNTH trades at $100.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas DNTH's P/E ratio is -24.22. In terms of profitability, VRAX's ROE is -1.03%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, VRAX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DNTH's competition here
VRAX vs MRTX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRAX is priced at $6.36, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRAX's ROE is -1.03%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRAX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check MRTX's competition here
VRAX vs DYN Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, DYN has a market cap of 4B. Regarding current trading prices, VRAX is priced at $6.36, while DYN trades at $24.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas DYN's P/E ratio is -7.54. In terms of profitability, VRAX's ROE is -1.03%, compared to DYN's ROE of -0.58%. Regarding short-term risk, VRAX is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check DYN's competition here
VRAX vs TLX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, TLX has a market cap of 4B. Regarding current trading prices, VRAX is priced at $6.36, while TLX trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas TLX's P/E ratio is -640.22. In terms of profitability, VRAX's ROE is -1.03%, compared to TLX's ROE of -0.02%. Regarding short-term risk, VRAX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TLX's competition here
VRAX vs CPRX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VRAX is priced at $6.36, while CPRX trades at $31.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas CPRX's P/E ratio is 11.32. In terms of profitability, VRAX's ROE is -1.03%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VRAX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check CPRX's competition here
VRAX vs TNGX Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, VRAX is priced at $6.36, while TNGX trades at $30.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas TNGX's P/E ratio is -36.77. In terms of profitability, VRAX's ROE is -1.03%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, VRAX is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check TNGX's competition here
VRAX vs RYZB Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRAX is priced at $6.36, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRAX's ROE is -1.03%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRAX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check RYZB's competition here
VRAX vs ALMS Comparison July 2026
VRAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRAX stands at 1.2M. In comparison, ALMS has a market cap of 3.7B. Regarding current trading prices, VRAX is priced at $6.36, while ALMS trades at $30.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRAX currently has a P/E ratio of -0.10, whereas ALMS's P/E ratio is -7.73. In terms of profitability, VRAX's ROE is -1.03%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, VRAX is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for VRAX.Check ALMS's competition here